Genedrive

Welsh hospitals extend routine clinical service of genedrive's MT-RNR1 test

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, is conducting a ShareSoc webinar at 11:00am (BST) today.

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company announces that on 28 August 2026, Dr Gino Miele, Chief Executive Officer, acquired 700,000 Ordinary Shares in the Company at a price of 1.38p pe

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, today announces that Mr Mark Winkler and Mr Mike Fairbourn have agreed to join the Board as independent Non-Executive Directors with effect fro

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, is pleased to announce that it will be presenting a live ShareSoc webinar on Thursday 3 September 2026 at 11:00am (BST).

Completion of PALOH-UK Patient Recruitment for Genedrive® MT-RNR1 ID Kit

Genedrive® MT-RNR1 ID Kit implemented at Erasmus MC University Medical Center in the Netherlands

New UK clinical guideline published for MT-RNR1 genotype testing

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, today announces that Mr.

- Strong commercial progress and poised for continued growth in the next 12 months

UK Health Minister highlights NIHR Manchester Biomedical Research Centre's adoption of rapid pharmacogenetic testing for antibiotic-induced hearing loss during Parliamentary Committee

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, today announces that further to the Company's announcement of 26 May 2026 detailing various immediate and proposed board changes, Dr.

CYP2C19 Product Development Collaboration agreement with Thermo Fisher Scientific Inc.

Manchester University NHS Foundation Trust transitions genedrive's MT-RNR1 test to Business as Usual clinical service

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, confirms it has received an R&D tax credit refund of approximately £0.76m from HMRC in respect of the financial years ended 30 June 2024 and 30

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, today announces that Mr David Nugent has joined the Board as a Non-Executive Director with immediate effect.

University Hospitals Sussex NHS Foundation Trust transitions genedrive's MT-RNR1 test to Business as Usual clinical service

Consultation to inform NHS England commercial strategy for rapid MT-RNR1 testing

genedrive Updates Interactive Investor Hub to Support Shareholder Engagement

Implementation of Genedrive® CYP2C19 ID Kit in North Bristol NHS Trust Southmead Hospital

- Capitalised to expand commercial operations in the UK and internationally

Manchester, UK - 9 March 2026: genedrive plc (LSE: GDR), the point of care pharmacogenetic testing company, announces that that it has conditionally raised total gross proceeds of approximately £0.91 million through the

Manchester, UK - 13 February 2026: genedrive plc (LSE: GDR), the point of care pharmacogenetic testing company, announces the completion of the placing (the "Placing") which was announced earlier today.

Proposed Direct Subscription to raise up to £3.5 million, Placing to raise up to £0.5 million and an Open Offer to raise up to circa £1.5 million to support various growth initiatives (the "Fundraising")

Significant indicated support from two major shareholders for an equity raise of up to £6.0 million

Genedrive's CYP2C19 ID kit piloted as a "test of change" in Scotland NHS Grampian and Western Isles

genedrive plc (LSE: GDR), the point of care pharmacogenetic testing company, is pleased to announce the launch of our interactive investor hub.

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, is pleased to announce that further to the announcement of 19 November 2025 confirming that heads of term had been agreed for a potential share

Annual Report and Accounts and date of AGM

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, announces its audited Final Results for the year ended 30 June 2025.

Pilot Programme Study Results underpinning NHS Implementation Guide for CYP2C19 Genotype Testing Presented at the UK Stroke Forum

NHS implementation guide published for CYP2C19 genotype testing

Scotland national roll-out of Genedrive® MT-RNR1 ID Kit

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, is pleased to announce that further to the announcement of 31 October 2025 in relation to a potential shareholder loan (the "Loan") from David

Genedrive® MT-RNR1 ID Kit implemented at Dublin's Rotunda Hospital

genedrive plc (AIM: GDR), the point-of-care pharmacogenetic testing company, today announces an update regarding discussions with David Nugent, a 16% shareholder in the Company including via a limited company.

Memorandum of Understanding with Kingdom of Saudi Arabia Ministry of Health

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, confirms that warrants have been exercised that were issued in connection to the Equity Prepayment facility that was announced on 31 March 2023

genedrive plc (LSE: GDR) Further to the Company's announcement on 6 October 2025 the Company has noted extensive postings on online bulletin boards which it believes to be made by David Nugent ("the Shareholder"), a 10.1

genedrive plc (LSE: GDR), the point of care pharmacogenetic testing company today responds to comments and speculation on online bulletin boards that other financing options may have been available to the Company and/or